Adakveo
Chemical Name | crizanlizumab-tmca |
Dosage Form | Injectable (intravenous; 10 mg/mL) |
Drug Class | Monoclonal antibodies |
System | Blood |
Company | Novartis |
Approval Year | 2019 |
Indication
- Adakveo is indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.